Conference Coverage
'Favorable signal' for secondary coronary prevention in STABILITY
Major finding: The combined rate of cardiovascular death, myocardial infarction, or stroke in patients randomized to darapladib was 9.7%, yielding...
WASHINGTON – In the large STABILITY trial, darapladib did not significantly reduce the primary endpoint of cardiovascular death, MI, or stroke in patients with stable coronary disease.
The novel selective oral inhibitor of lipoprotein-associated phospholipase A has been shown to reduce the enzyme by 60%. The aim of this study was to reduce it within coronary plaque.
Despite the negative outcome, investigator Dr. Harvey D. White told us in an interview at the annual meeting of the American College of Cardiology that there is more to learn about darapladib, as a secondary endpoint of reducing cardiovascular death, MI, and urgent revascularization was nominally significant.